Public Health.

Background: Disease modifying therapies (DMTs) for Alzheimer's disease (AD) have been approved in some countries although these treatments will require substantial health resources for their implementation. Initial capacity planning to identify the resources required to support DMTs begins with estimating the number of people with dementia who may be eligible for DMTs. We estimated the potential number of individuals with dementia who are eligible for DMTs using population-based data in Alberta, Canada.

Public Health.

Background: Potential disease modifying therapies (DMT) for Alzheimer's disease (AD) may become available in Canada although it is unclear what percentage of people presenting to tertiary care memory programs may require beta-amyloid testing be eligible for these treatments. We evaluated eligibility for potential DMTs among individuals in the Prospective Registry for Persons with Memory Symptoms (PROMPT) dementia research registry, comprising patients seen in a tertiary care cognitive clinic in Calgary, Alberta, Canada, based on cognitive criteria, medical history, and potential diagnosis of AD on clinical criteria.

Method: We analyzed all individuals included in the PROMPT registry from July 2010 to May 2023 who were diagnosed with either mild cognitive impairment (MCI) or possible or probable dementia at their baseline assessment.

Dementia Care Research and Psychosocial Factors.

Background: The overuse of antipsychotics in persons with dementia in long-term care (LTC) has been a source of clinical concern, public attention, and policy intervention for over 30 years. Targeted quality improvement, broader awareness of risks, and other initiatives have resulted in substantial reductions in antipsychotic use in LTC settings in North America and elsewhere. Limited evidence suggests that reductions in antipsychotic use may be resulting in unintended consequences, such as substitution with alternate, but similarly harmful, psychotropic medications.